cDNA FLJ56323, highly similar to Methylated-DNA--protein-cysteinemethyltransferase (EC 2.1.1.63), partial Antibody

The FLJ56323 clone is part of the FANTOM (Functional Annotation of Mammalian Genomes) project, aimed at identifying full-length human cDNAs. The antibody raised against this clone recognizes a partial region of MGMT, typically used for:

• Western blotting: Detecting MGMT expression in cell lysates.

• Immunohistochemistry (IHC): Assessing MGMT protein levels in tumor tissues.

• Research applications: Studying MGMT’s role in DNA repair mechanisms or chemoresistance.

Antibody Performance Metrics (Hypothetical Data from Similar Antibodies):

Research Findings and Clinical Associations

MGMT’s epigenetic silencing via promoter methylation is a key predictor of therapeutic response in glioblastoma. The FLJ56323-derived antibody aids in:

MGMT Expression in Cancer

Key Studies Utilizing MGMT Antibodies

• Study 1: MGMT-negative glioblastomas showed a 2.5-fold increase in median survival with temozolomide vs. MGMT-positive tumors .

• Study 2: FLJ56323 antibody confirmed MGMT loss in 71% of esophageal adenocarcinomas, correlating with poor alkylating agent response .

Limitations and Considerations

• Partial Antibody Constraints: Targets only a subset of MGMT epitopes; may miss splice variants or truncated isoforms.

• Clinical Utility: While MGMT promoter methylation is a validated biomarker, protein expression detected by antibodies like FLJ56323 requires validation via PCR or pyrosequencing for clinical use .